Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.1% – Here’s Why

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price fell 6.1% during trading on Thursday . The company traded as low as $21.30 and last traded at $21.20. 227,654 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 837,960 shares. The stock had previously closed at $22.57.

Wall Street Analyst Weigh In

A number of brokerages have commented on GPCR. William Blair began coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target on the stock. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Stock Performance

The stock has a market capitalization of $1.25 billion, a P/E ratio of -29.47 and a beta of -2.37. The stock has a 50-day moving average price of $24.99 and a two-hundred day moving average price of $32.03.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently made changes to their positions in GPCR. ANTIPODES PARTNERS Ltd boosted its position in shares of Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics during the fourth quarter valued at approximately $34,000. FNY Investment Advisers LLC bought a new stake in shares of Structure Therapeutics during the fourth quarter valued at approximately $40,000. Finally, Virtus ETF Advisers LLC boosted its holdings in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after acquiring an additional 455 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.